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Letters to the Editorsubsequent reduction of renal blood
flow observed during hypothermia
are probably unrelated to increased
levels of circulating catecholamines
or increased renal sympathetic nerve
activity. Other metabolic process tak-
ing place in response to lowering of
temperature have been proposed.4
Overall, the clinical evidence re-
garding the potential benefits of hypo-
thermia during pediatric heart surgery
are not convincing. In fact, there is in-
creasing retrospective evidence5
showing several benefits of normo-
thermic cardiopulmonary bypass.
Our own study has provided the first
randomized trial evidence of the im-
pact of normothermic cardiopulmo-
nary bypass on renal function,
contributing to the accumulating evi-
dence of this technique in a low-risk
group of children undergoing heart
surgery.
Much more work is needed if we
are to understand whether normother-
mia is safe in patients at higher risk,
such as neonates and patients with
complex congenital heart disease,
who are more likely to be affected
by cardiopulmonary bypass–induced
postoperative renal dysfunction.
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COMPLICATIONS IN PATIENTS
WITH HETEROTAXY
SYNDROME
To the Editor:
We read the interesting paper by
Swisher and associates1 on the respira-
tory complications after cardiac surgery
in patients with heterotaxy syndrome.
The authors compared the postoperative
course of children with heterotaxy syn-
dromewith that of patients with cardiac
defects and similar surgical complex-
ities following the Risk Adjustment
in Congenital Heart Surgery.1,2
The patients with heterotaxy syn-
drome showed higher surgical mortal-
ity and increased postoperative
respiratory complications including
postoperative hospital stay, longer
mechanical ventilation, need for tra-
cheostomies, and extracorporealmem-
brane oxygenation support.1 Other
very recent articles underlined specific
problems and specific surgical solu-
tions in children with heart disease
and laterality defects.3,4 All these
observations confirm the notion that
the presence of genetic syndromes
may significantly affect the
perioperative management of patients
with congenital heart defect.5
As described for patients with
trisomy 21, deletion 22q11, Turner
syndrome, and other genetic syn-
dromes,5 the knowledge of specific
cardiovascular and extracardiac de-
fects deserves particular attention in
the perioperative period in terms of
specific diagnostic, operative, and in-
tensive care protocols.
Heterotaxy syndrome characterized
by complex cardiovascular malforma-
tions and extracardiac defects deserves
specific cardiac and extracardiac pre-
operative assessment to recognize
risk factors and to reduce theof Thoracic and Cardiovascular Surgeoperative mortality and postoperative
complications.1,3,4
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We thank Dr Martucci and her col-
leagues for their supportive letter,
which emphasizes the general point
that the presence of genetic syn-
dromes may significantly affect the
perioperative management of patients
with a congenital heart defect. Specif-
ically for patients with heterotaxy, we
agree that these complex patients re-
quire ‘‘cardiac and extracardiac pre-
operative assessment to recognize
risk factors and to reduce the operative
mortality and postoperative complica-
tions.’’ Extrapolating beyond the
phenotype–genotype–prognosis para-
digm of their cited reference,1 we
suggest adding ‘‘therapy’’ to the
paradigm.ry c Volume 143, Number 3 759
Letters to the EditorPatients in our study with heterotaxy
and congenital heart disease (CHD)
showed high postoperative morbidity/
mortality, with some having respiratory
complications.2 Although this respira-
tory phenotype is often attributed to
the CHD, airway mucus clearance and
left-right patterning, abnormal in heter-
otaxy syndrome, both require motile
ciliary function. Thus airway ciliary
dysfunction (CD) similar to that of pri-
mary ciliary dyskinesia (PCD) may
have relevance for increased respiratory
complications seen in patientswith het-
erotaxy. To better characterize the phe-
notype of a broad spectrum of patients
with heterotaxy, 43 patients with CHD
were assessed for airway CD. We
used videomicroscopy to look for ab-
normal ciliary motion in nasal tissue
and nasal nitric oxide noninvasive test-
ing (typically low with PCD) to assess
for CD. A remarkable 42% (18/43) of
patients exhibited CD, with one third
in the severe PCD range. Patients
greater than 6 years old with CD
showed increased respiratory disease
similar to that seen in PCD.3 Our stud-
ies suggest patients with CHD who
have heterotaxy have substantial risk
of CD and respiratory disease that
complicates their prognosis.
The phenotype–genotype–progno-
sis correlation is also important in
that further research may allow future
patients and families to correlate gene
mutations with phenotype and progno-
sis. Now families face the very high re-
currence risk ratio of 79.1 for
heterotaxia (95% confidence interval,
32.9-190).4 Further study of our pa-
tients with heterotaxy who have CD
through next-generation sequencing
of all 14 known PCD genes in 13 heter-
otaxy patients with CD identified 10
novel coding variants in 6 PCD genes.
Recently, some CD gene mutations
have become commercially available.
The paradigm of phenotype–geno-
type–prognosis is beneficial to pro-
mote translational research to the
patient, family, and medical care
team. Our research suggests that pa-
tients with CHD and heterotaxy will760 The Journal of Thoracic and Cbe at higher perioperative risk if they
have CD.3 These findings indicate
that patients with CHD and heterotaxy
may benefit from preoperative screen-
ing for CD. Recognition of specific
surgical risks factors in genetic syn-
dromes is leading to specific diagnostic
protocols that improve phenotyping or
predictive genotyping.1 To add ‘‘ther-
apy’’ to the paradigm, further studies
are needed to evaluate whether perio-
perative protocols improving airway
ciliary motility and enhancing mucus
clearancemay reduce respiratory com-
plications and improve postoperative
outcome for patients with CHD who
have heterotaxy and CD.
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AMPLATZER SEPTAL
OCCLUDER DEVICE
To the Editor:
We read with interest the article
‘‘Late erosion of an Amplatzer septalardiovascular Surgery c March 2012occluder device 6 years after place-
ment’’ by Taggart, Dearani, and
Hagler1 in the Journal of Thoracic
and Cardiovascular Surgery.
It is assumed that cardiac perfora-
tion is a rare complication following
transcatheter device closure of an atrial
septal defect (ASD) or patent foramen
ovale (PFO). We, too, had a patient
who had similar complications of per-
foration 9 months after closure of an
ASD with a BioSTAR septal occluder
(NMT Medical, Boston, Mass).2 An-
other patient came to us 3 years after
ASD closure with a Solysafe device
(Swissimplant AG, Solothurn, Swit-
zerland) with complications of device
fracture and embolization into the pul-
monary artery. Our patients warranted
emergency surgical exploration for de-
vice explantation, repair of the erosion,
along with pericardial patch closure of
the residual septal defect. Although in-
novative absorbable closure devices
that gradually biodegrade after implan-
tation have theoretically decreased the
long-term complications, it must be
borne in mind that these devices are
not totally bioabsorbed. The nonab-
sorbable components, such as the
metal struts, may create long-term
complications by eroding into the adja-
cent tissues.
This case clearly illustrates that in-
asmuch as tissue erosion, and other
complications such as strut fracture,
may occur at any time starting from
72 hours to 6 years after implantation,
echocardiographic follow-up is
needed, not just in the early stages,
but also in the long-term. We also be-
lieve that clearer guidelines and rec-
ommendations may help prevent the
complications associated with septal
occluder devices.
Although cardiac perforation may
be ‘‘rare,’’ it is a potentially ‘‘seri-
ous’’ complication after transcatheter
device closure procedures. These pa-
tients arrived at the hospital in time
to benefit from immediate diagnosis
and emergency surgical treatment of
their complications. The question
we need to ask ourselves and also
